[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rectal-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rectal-cancers":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100639861","phase-2-neoadjuvant-radiotherapy-combined-with-nalirifox-and-adebrelimab-in-pmmrmss-locally-advanced-rectal-cancer-a-prospective-randomized-phase-ii-clinical-trial-100639861",false,"NCT07622771","Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR\u002FMSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial","Inclusion Criteria:\n\n1. Patients or their family members agree to participate in the study and sign the informed consent form;\n2. Age 18-75 years, male or female;\n3. Locally advanced rectal adenocarcinoma confirmed by histopathology;\n4. Clinical stage cT3-4bN0M0 or cTxN+M0, with or without MRF positive, with or without EMVI positive, expected to R0 resection;\n5. without intestinal obstruction;\n6. ECOG PS 0-1;\n7. expect survival up to 2 years;\n8. White blood cell count \\> 3.5×109\u002FL；Platelet count ≥ 100×109\u002FL；Hemoglobin ≥ 80 g\u002FL；\n9. ALT ≤ 1.5×ULN, AST ≤ 1.5×ULN ；\n10. Serum creatinine ≤ 100μmol\u002Fl,\n\nExclusion Criteria:\n\n1. With inguinal lymph node metastasis or lateral lymph node metastasis (lymph node diameter ≥7 mm, or lymph node morphology and MRI features consistent with typical metastatic lymph nodes);\n2. Arrhythmia requiring antiarrhythmic treatment (except beta-blockers or digoxin), symptomatic coronary artery disease or myocardial ischemia (myocardial infarction within the last 6 months), or congestive heart failure exceeding NYHA Class II;\n3. Severe hypertension poorly controlled with medication;\n4. History of HIV infection, or active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 10⁴ copies\u002FmL), or hepatitis C (positive hepatitis C antibody with HCV-RNA above the lower limit of detection of the assay);\n5. Active pulmonary tuberculosis (TB), currently receiving anti-tuberculosis treatment, or having received anti-tuberculosis treatment within 1 year prior to screening;\n6. Other active clinically severe infections (NCI-CTCAE Version 5.0);\n7. Preoperative evidence of distant metastasis outside the pelvis;\n8. Cachexia or organ function decompensation.\n9. History of pelvic or abdominal radiotherapy;\n10. Multiple primary colorectal cancers;\n11. Patients with seizures requiring treatment (e.g., corticosteroids or antiepileptic therapy);\n12. History of other malignancies within 5 years, except cured cervical carcinoma in situ or basal cell carcinoma of the skin;\n13. Drug abuse, or medical, psychological, or social conditions that may interfere with the patient's participation in the study or affect the evaluation of study results;\n14. Active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enterocolitis, hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism);\n15. Receipt of any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine, etc.) within 4 weeks prior to enrollment;\n16. Comorbidities requiring long-term treatment with immunosuppressive agents, or requiring systemic or local administration of corticosteroids at immunosuppressive doses (dose \\>10 mg\u002Fday of prednisone or other glucocorticoids with equivalent efficacy);\n17. Known or suspected hypersensitivity to the investigational drug, or to any medication administered in relation to this study;\n18. Any unstable condition that may jeopardize patient safety or compliance;\n19. Pregnant or lactating women, or women of childbearing potential not using adequate contraception;\n20. Refusal to sign the informed consent form.","ALL","18 Years","75 Years",{"count":19,"type":20},84,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","To explore the efficacy and safety of radiotherapy combined with Adebrelimab and NALIRIFOX in patients with pMMR\u002FMSS locally advanced rectal cancer",[26],"Rectal Cancers",[28,29,30,31],"radiotherapy","immunotherapy","neoadjuvant therapy","rectal cancer","NOT_YET_RECRUITING","2026-05-28",{"date":35,"type":36},"2026-06-03","ACTUAL",{"date":38,"type":20},"2026-06-01",{"date":40,"type":20},"2032-12-31",{"name":42,"class":43},"Sun Yat-sen University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100632632","phase-2-adaptive-radiotherapy-for-safe-hypofractionation-100632632","NCT07516210","Adaptive Radiotherapy for Safe Hypofractionation","Adaptive Radiotherapy for Safe Hypofractionation (ART-Hypo): A Bayesian Registry-Based Randomized Controlled Trial","ART-Hypo","Inclusion Criteria:\n\n\\- Enrolled in PERa registry (CHUM CER 17.0.32), consented to contact for investigational trials, consented to serve as control, and randomly selected to be offered the experimental intervention.\n\nExclusion Criteria:\n\n\\- For intact prostate stratum : 1. Contraindications to MRI (e.g., pacemaker, potentially mobile metal implant, claustrophobia). 2. Hip replacement, or other pelvic metalwork which causes significant artefact on MRI.",{"count":54,"type":20},264,[23],"This phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) evaluates whether daily online adaptive radiotherapy (ART) enables the safe delivery of hypofractionated, iso-biologically equivalent (EQD2) external beam radiotherapy compared with standard-of-care (SOC) fractionation.\n\nConventional radiotherapy requires generous planning target volume (PTV) margins to account for inter-fraction anatomical variation, which increases radiation exposure to surrounding organs at risk (OARs) and may contribute to toxicity. Modern ART platforms using daily on-table imaging (kV-CBCT or MRI guidance) allow real-time contour adaptation and online plan re-optimization based on same-day anatomy. This approach enables margin reduction while maintaining target coverage and may permit safe hypofractionation.\n\nEligible patients enrolled in an institutional prospective registry will be randomized (1:1) to receive either SOC radiotherapy or hypofractionated ART across multiple pelvic disease strata (post-prostatectomy prostate cancer, intact prostate cancer, endometrial cancer, cervical cancer, and rectal cancer).\n\nThe primary objective is to demonstrate non-inferiority of hypofractionated ART compared with SOC in terms of cumulative incidence of Grade ≥2 toxicity (CTCAE v5). Secondary outcomes include acute and late toxicity, oncologic outcomes (progression-free survival, locoregional failure, distant metastases, overall survival), patient-reported outcomes, treatment efficiency, and dosimetric parameters.\n\nA Bayesian monitoring framework with pre-specified safety and futility stopping rules will be used to ensure patient safety and clinical equipoise throughout the trial.",[58,59,60,61,26],"Cancer","Endometrial Cancer","Prostate Cancer","Cervical Cancer","2026-04-02",{"date":64,"type":36},"2026-04-07",{"date":66,"type":20},"2026-05",{"date":68,"type":20},"2030-05",{"name":70,"class":43},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":44},"100630940","mimicc-study-in-patients-with-colorectal-cancer-100630940","NCT07494201","MIMICC Study in Patients With Colorectal Cancer","Analysis of MicroRNA Expression and Microbiome Composition During the Diagnostic-Therapeutic Pathway of Patients With Colorectal Carcinoma","MIMICC","Inclusion Criteria:\n\n* Histologically confirmed colon or rectal cancer on endoscopic biopsy\n* Any T stage, any N stage, M0-M1, candidate for surgical intervention\n* Colon tumors with indication for surgical resection with curative intent, including right hemicolectomy, left hemicolectomy, transverse colon resection, colectomy, or total proctocolectomy\n* Rectal tumors with indication for upfront surgery or neoadjuvant chemoradiotherapy\n* Written informed consent signed before any study procedure\n* Age between 18 and 75 years\n\nExclusion Criteria:\n\n* Tis\u002FT1 lesions or lesions almost completely resected by endoscopic polypectomy\u002FEMR\u002FESD\n* Use of immunosuppressive or immunomodulatory drugs within the previous 6 months\n* Current or previous diagnosis of other solid or hematologic malignancies\n* Inability or refusal to provide informed consent\n* Inability or refusal to be followed at the study institution\u002Fnetwork",{"count":80,"type":20},2500,[82],"NA","This multicenter prospective interventional study will evaluate stool and saliva microRNA expression and microbiome composition in patients with histologically confirmed colon or rectal cancer during key phases of the diagnostic and therapeutic pathway. The study aims to confirm and refine molecular signatures associated with colorectal cancer, assess the diagnostic and prognostic potential of salivary biomarkers, and characterize dynamic molecular changes during treatment and follow-up",[85,86,26],"Colorectal Cancer","Colon Cancer",[88,89,90,91,92,93,94,95],"microRNA","microbiome","stool biomarkers","saliva biomarkers","colorectal cancer","anastomotic leak","diet","recurrence","RECRUITING","2026-03-20",{"date":99,"type":36},"2026-03-27",{"date":101,"type":36},"2025-09-15",{"date":103,"type":20},"2028-06-30",{"name":105,"class":43},"Fondazione del Piemonte per l'Oncologia","Rectal Cancers."]